Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 4, 2012, Pages 361-365

  Cardoso Bourguignon da Silva, Dáfne ^a   Toribio Finoti Seixas, Gláucia ^a   Ribeiro de Araujo, Orlei ^a   Arduini, Rodrigo Genaro ^a   de Moraes Costa Carlesse, Fabianne Altruda ^a   Sergio Petrilli, Antonio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti bacterial agents; Drug resistance; Immunosuppression; Microbial; Pharmacokinetics; Staphylococcus

Indexed keywords

VANCOMYCIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BAYES THEOREM; CALCULATION; CANCER PATIENT; CHILDHOOD CANCER; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFANT; INTENSIVE CARE; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INFANT; INTENSIVE CARE; MALE; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 84864366228     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.06.011     Document Type: Article

References (19)

1. Bailey L.C., Reilly A.F., Rheingold S.R. Infections in pediatric patients with hematologic malignancies. Semin Hematol 2009, 46:313-324.
2. Wisplinghoff H., Seifert H., Wenzel R.P., Edmond M.B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003, 36:1103-1110.
3. Rolston K.V. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005, 40(Suppl 4):S246-S252.
4. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
5. Reis A.G., Grisi S.J. Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections. J Pediatr (Rio J) 1996, 72:225-229.
6. Deresinski S. Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections?. Int J Antimicrob Agents 2009, 34(Suppl 4):S43-S46.
7. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
8. Cruciani M., Gattr G., Lazzarini L., Furlan G., Broccali G., Malena M., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996, 38:865-869.
9. Horne K.C., Howden B.P., Grabsch E.A., Graham M., Ward P.B., Xie S., et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009, 53:3447-3452.
10. Kitzis M.D., Goldstein F.W. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006, 12:92-95.
11. Pea F., Furlanut M., Negri C., Pavan F., Crapis M., Cristini F., et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009, 53:1863-1867.
12. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
13. Simons S.A., Molinelli A.R., Sobhani K., Rainey P.M., Hoofnagle A.N. Two cases with unusual vancomycin measurements. Clin Chem 2009, 55:578-582.
14. Schwartz G.J., Feld L.G., Langford D.J. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984, 104:849-854.
15. Piro C.C., Crossno C.L., Collier A., Ho R., Koyama T., Frangoul H. Initial vancomycin dosing in pediatric oncology and stem cell transplant patients. J Pediatr Hematol Oncol 2009, 31:3-7.
16. Lamarre P., Lebel D., Ducharme M.P. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother 2000, 44:278-282.
17. Lepe J.A., Gil-Navarro M.V., Santos-Rubio M.D., Bautista J., Aznar J. Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant. Rev Esp Quimioter 2010, 23:43-47.
18. Petrosillo N., Drapeau C.M., Agrafiotis M., Falagas M.E. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol 2010, 76:509-524.
19. Buelga D.S., del Mar Fernandez de Gatta M., Herrera E.V., Dominguez-Gil A., García M.J. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 2005, 49:4934-4941.